ライフサイエンスコーパス: perfluorocarbon

1 kes each for heliox (70:30 mixture), NO, and perfluorocarbon.

2 h standardized volumes of either room air or perfluorocarbon.

3 safely with minute quantities of intravenous perfluorocarbon.

4 n elucidation of the solvophobic behavior in perfluorocarbon.

5 ttraction for the aqueous interface, such as perfluorocarbons.

6 quid ventilation with temperature-controlled perfluorocarbons.

7 hemoglobin-based oxygen carriers (HBOCs) and perfluorocarbons.

8 tion of CO2 and 0.64-0.76 mL.min(-1) loss of perfluorocarbon across the fibers.

9 This study suggests that different perfluorocarbons affect adhesions differently.

10 were injected with a commercially available perfluorocarbon and were examined in vivo with an 11.7-T

11 mbine two tools which rely on orthogonality- perfluorocarbons and multiplexed shortwave infrared (SWI

12 Anions derived from perfluorocarbons appear to be directly applicable to mix

13 Intravenously administered perfluorocarbons are taken up by infiltrating inflammato

14 There is considerable interest in the use of perfluorocarbons as oxygen carriers in clinical settings

15 s ventilation (control, n=9) or to institute perfluorocarbon-associated gas exchange (n=9) by instill

16 ants of gas exchange would be similar during perfluorocarbon-associated gas exchange and conventional

17 dult sheep with acid aspiration lung injury, perfluorocarbon-associated gas exchange at an FIO2 of <1

18 We hypothesized that a) perfluorocarbon-associated gas exchange could be accompl

19 lation; c)in large animals with lung injury, perfluorocarbon-associated gas exchange could be used to

20 er, survival was significantly higher in the perfluorocarbon-associated gas exchange group with eight

21 osis (p<.05), while pH did not change in the perfluorocarbon-associated gas exchange group.

22 essure directly influence oxygenation during perfluorocarbon-associated gas exchange in large animals

23 ventilation determined CO2 clearance during perfluorocarbon-associated gas exchange in normal sheep.

24 After acid aspiration lung injury, perfluorocarbon-associated gas exchange increased PaO2 a

25 Five normal ewes (61.0 +/- 4.0 kg) underwent perfluorocarbon-associated gas exchange to ascertain the

26 Within 15 mins of initiating perfluorocarbon-associated gas exchange, oxygenation inc

27 nfluenced oxygenation in normal sheep during perfluorocarbon-associated gas exchange.

28 uld be supported with an FIO2 of <1.0 during perfluorocarbon-associated gas exchange.

29 cs were not influenced by the institution of perfluorocarbon-associated gas exchange.

30 short-chain and ultra-short-chain PFASs (<=2 perfluorocarbon atoms for PFCAs, <=3 for PFSAs and other

31 Here, we describe the formulation of perfluorocarbon-based nanoemulsions with improved sensit

32 iguous understanding of the oleophobicity of perfluorocarbon chain in PFOS, and it is helpful for the

33 the order of PFSAs > PFCAs > PFPAs of equal perfluorocarbon chain length and was dependent on the ch

34 Perfluorocarbon chain of perfluorooctane sulfonate (PFOS

35 The perfluorocarbon chain repels hydrophobic compounds and i

36 ces of air bubbles with the hydro-oleophobic perfluorocarbon chain stretching into air bubbles and th

37 otic-free, fluoropolymer-immobilized, liquid perfluorocarbon-coated peripherally inserted central cat

38 In 5 additional animals, perfluorocarbon combined with FITC (fluorescein isothioc

39 10 to 20 Hz) after intravenous injections of perfluorocarbon containing microbubbles has the potentia

40 ts of core-shell nanoparticles with a liquid perfluorocarbon core and a mesoporous silica shell ((19)

41 ivo accumulation of semipermeable 200-300 nm perfluorocarbon core nanoparticles (PFC-NP) in ApoE null

42 c resonance spectroscopy of the nanoparticle perfluorocarbon core, yielding a quantitative estimate o

43 nt consisting of a lipid shell with a liquid perfluorocarbon core.

44 NO at 25 ppm and perfluorocarbon did not interfere with the accuracy of a

45 The presence of perfluorocarbon did not interfere with the MDA assay whe

46 The perfluorocarbon dose was repeated daily for a total of 3

47 (19)F MRS of a perfluorocarbon droplet provides an accurate measure of

48 re labeled by intravenous injection of (19)F-perfluorocarbon emulsion 1 day after MI.

49 e measured experimentally by incorporating a perfluorocarbon emulsion in the beads and acquiring (19)

50 Perfluorocarbon emulsion nanodroplets containing iron ox

51 We report preparation of perfluorocarbon emulsion polyplexes containing a fluorin

52 The use of perfluorocarbon emulsion polyplexes to achieve combined

53 The agent is a biotinylated, lipid-coated, perfluorocarbon emulsion that has low inherent echogenic

54 of IONPs into the fluorous phase of a liquid perfluorocarbon emulsion would potentiate acoustic vapor

55 Perfluorocarbon emulsions (PFCEs) have high O2-dissolvin

56 Perfluorocarbon emulsions activate complement and cause

57 ed on either hemoglobin (animal or human) or perfluorocarbon emulsions are in advanced stages of clin

58 ulfate for detection by X-ray modalities; or perfluorocarbon emulsions for multimodal detection by (1

59 ions of modified cell-free hemoglobin and of perfluorocarbon emulsions have demonstrated significant

60 Safe doses of perfluorocarbon emulsions have very limited oxygen-carry

61 velopment are based on cell-free hemoglobin, perfluorocarbon emulsions, or liposome-encapsulated hemo

62 o avidin and then to biotinylated or control perfluorocarbon emulsions.

63 approach with intravenous administration of perfluorocarbon-exposed sonicated dextrose albumin (PESD

64 We have shown previously that perfluorocarbon-exposed sonicated dextrose albumin (PESD

65 ntermittent harmonic imaging and intravenous perfluorocarbon-exposed sonicated dextrose albumin contr

66 ial contrast after intravenous injections of perfluorocarbon-exposed sonicated dextrose albumin micro

67 nd contrast can be produced from intravenous perfluorocarbon-exposed sonicated dextrose albumin, and

68 acterial adhesion and viability after liquid perfluorocarbon exposure and to assess bacterial recover

69 f the potential implications of intrauterine perfluorocarbon exposure during critical periods of feta

70 Continuous perfluorocarbon exposure with this method is reproducibl

71 ts with a previous MI using bolus doses of a perfluorocarbon-filled contrast agent (NC100100).

72 Gas ventilation of the perfluorocarbon-filled lungs (partial liquid ventilation

73 Lipid-shell perfluorocarbon-filled MBs, targeted to VEGFR2 via anti-

74 integrin, or both antibodies to the shell of perfluorocarbon-filled MBs.

75 attaching Knottin(Integrin) to the shell of perfluorocarbon-filled microbubbles (MB-Knottin(Integrin

76 PCCAs are lipid-coated, perfluorocarbon-filled particles formulated as nanoscale

77 diography by using an intravenous bolus of a perfluorocarbon-filled, albumin-(Optison: n = 98) or lip

78 ese requirements but have high resistance to perfluorocarbon flow and high priming volume.

79 image nanoscale lipid and polymer-stabilized perfluorocarbon gas bubbles before and after their destr

80 MBs were prepared by emulsification of perfluorocarbon gas in phospholipids and decorated with

81 was performed using intravenous injection of perfluorocarbon gas-containing microbubbles during two-d

82 microspheres (2-micron diameter) filled with perfluorocarbon gas.

83 duced dissipation of nanobubble encapsulated perfluorocarbon gas.

84 hers approximately sulfur/carbon compounds > perfluorocarbons > perfluoroolefins > carbon/nitrogen co

85 itive emulsion droplets composed of a liquid perfluorocarbon have the potential to be a highly effici

86 cence recovery after photobleaching, using a perfluorocarbon immersion lens and confocal fluorescence

87 and flow cytometry confirmed the presence of perfluorocarbon in macrophages, dendritic cells, and gra

88 ultrasonography (US) after the inclusion of perfluorocarbon in the capsules.

89 nt for Xe NMR based on surfactant-stabilized perfluorocarbon-in-water nanoemulsions has been produced

90 adiolabeled Escherichia coli were exposed to perfluorocarbon, incubated against artificial biosurface

91 In the Liquid Warm group, perfluorocarbon inhalation did not alter infarct size co

92 compared with control animals, intratracheal perfluorocarbon instillation resulted in significant imp

93 Oxygen delivery improved with perfluorocarbon instillation, but this improvement was n

94 y exchanges between aqueous solution and the perfluorocarbon interior of the droplets, which are spec

95 led glioblastoma tumors were inoculated with perfluorocarbon-labeled CAR T cells or untransduced T ce

96 ed: (a) mice were injected in the flank with perfluorocarbon-labeled human glioblastoma cells and wer

97 The present study investigated variation in perfluorocarbon levels of 9952 women of childbearing age

98 Viscodissection or the utilization of perfluorocarbon liquid (PFCL) can be used to dissect the

99 nal detachment (RD) repair by vitrectomy and perfluorocarbon liquid (PFCL) tamponade.

100 This study aimed to evaluate the outcomes of perfluorocarbon liquid (PFCL) versus posterior retinotom

101 Inclusion criteria included iOCT after perfluorocarbon liquid (PFO) placement, visualization of

102 y isolating small-sized (diameter <6 microm) perfluorocarbon liquid droplets from polydisperse drople

103 The intratracheal administration of a perfluorocarbon liquid during continuous positive-pressu

104 ternative, perfluorotributylamine (PFTBA), a perfluorocarbon liquid for (19)F MRI thermometry, is bas

105 -layered ILM inverted flap assisted by a sub-perfluorocarbon liquid injection of ophthalmic viscoelas

106 The technique of using sub-perfluorocarbon liquid injection of OVD secured single-l

107 ted the preliminary results of using the sub-perfluorocarbon liquid ocular viscoelastic device inject

108 Inclusion criteria included iOCT after perfluorocarbon liquid placement and at least 6 months f

109 tion (PLV) with two different dosages of the perfluorocarbon LiquiVent (perflubron) on pulmonary vasc

110 Estimated in vivo perfluorocarbon loss from the device was 1.2 mL.min(-1).

111 mposite structure before applying the liquid perfluorocarbon (LP).

112 Perfluorocarbon may be safely administered into the lung

113 tly the intravenous (i.v.) administration of perfluorocarbon microbubbles has been shown to enhance o

114 After incubation with albumin-coated perfluorocarbon microbubbles, an adenovirus encoding a r

115 studied as candidate blood substitutes: the perfluorocarbons, modified hemoglobins, and liposome-enc

116 Low-boiling point perfluorocarbon nanodroplets (NDs) are valued as effecti

117 Our agent consists of liquid perfluorocarbon nanodroplets with encapsulated plasmonic

118 We present here the first perfluorocarbon nanoemulsion (PFC NE) that is designed t

119 , their utility was demonstrated by tracking perfluorocarbon nanoemulsion biodistribution in vivo.

120 an T cells were intracellularly labeled with perfluorocarbon nanoemulsion droplet sensors prior to in

121 pha2-antiplasmin peptide (alpha2AP)-targeted perfluorocarbon nanoemulsions (PFCs) as contrast agent,

122 Coupling of EP9 to perfluorocarbon nanoemulsions (PFCs) resulted in the eff

123 cyanine dye for tracking the localization of perfluorocarbon nanoemulsions in macrophage cells and fo

124 de)-co-polylactide micelles or corresponding perfluorocarbon nanoemulsions.

125 fluorofluorophores by preparing fluorescent perfluorocarbon nanoemulsions.

126 his strategy by generating a VCAM-1-targeted perfluorocarbon nanoparticle for in vivo targeting in at

127 melittin into the outer lipid monolayer of a perfluorocarbon nanoparticle.

128 particles for stem-cell tracking, multimodal perfluorocarbon nanoparticles for visualization of angio

129 low priming volume to minimize the amount of perfluorocarbon needed.

130 r intravenous injection of 2x200 microL of a perfluorocarbon on day 19 and 20 (n=9) after immunizatio

131 ch holds a thin liquid film of medical-grade perfluorocarbon on the surface.

132 as low as 100 fM, corresponding to <1 muL of perfluorocarbon per liter of solution.

133 vIII targeting transgene were labeled with a perfluorocarbon (PFC) emulsion ex vivo and infused into

134 Here, we advance our previously reported perfluorocarbon (PFC) emulsion polyplex platform by deve

135 lessons learned from initial attempts using perfluorocarbon (PFC) emulsions and acellular hemoglobin

136 Perfluorocarbon (PFC) emulsions were injected intravenou

137 The administration of a perfluorocarbon (PFC) liquid, such as perflubron, during

138 port the synthesis and formulation of unique perfluorocarbon (PFC) nanoemulsions enabling intracellul

139 oline) diblock copolymer surfactants to form perfluorocarbon (PFC) nanoemulsions that release cargo u

140 cells labeled with different types of liquid perfluorocarbon (PFC) nanoparticles produces unique and

141 The trend for the perfluorocarbon (PFC) radicals is quite different.

142 Oxygen carried in perfluorocarbon (PFC) was delivered to the TME, thus rel

143 Perfluorocarbons (PFC) are hydrocarbons in which all or

144 OE-mediated polarization of oxygen-sensitive perfluorocarbons (PFC) by laser-polarized (129)Xe gas at

145 erved in high-oxygen solution (preoxygenated perfluorocarbon [PFC] + University of Wisconsin [UW] sol

146 Perfluorocarbons (PFCs) are lipid emulsion particles wit

147 Perfluorocarbons (PFCs) are promising blood substitutes

148 stabilization of low-boiling point (low-bp) perfluorocarbons (PFCs) at physiological temperatures by

149 Perfluorocarbons (PFCs) exhibiting high solubility for o

150 Perfluorocarbons (PFCs) hold great promise for biomedica

151 d/or climate forcing, from the very volatile perfluorocarbons (PFCs, e.g., CF(4) and CH(3)CF(3)) and

152 to examine the requirements for designing a perfluorocarbon (PFT) monitoring network and tracer tagg

153 tectors: (1) sample confinement using liquid perfluorocarbon plugs to increase the observe factor, (2

154 er, if the sample is bracketed by two liquid perfluorocarbon plugs, the observe factor can be increas

155 Liquid ventilation with perfluorocarbon previously has not been reported in pedi

156 Cell-specific Po(2) measurements using perfluorocarbon probes can provide insights into effecto

157 The bioorthogonal nature of perfluorocarbons provides a unique platform for introduc

158 Using a perfluorocarbon purification handle, we were able to pur

159 ved from both PFCAs, suggesting formation of perfluorocarbon radical intermediates.

160 including R = alkyl, hydroxy, phenyl, ester, perfluorocarbon) reported here derives from a single, re

161 ough fluorophilic interactions of a blend of perfluorocarbon (RF) end-functionalized polystyrene and

162 results indicate that at 25 degrees C in the perfluorocarbon-rich phase, both solvent components inte

163 Perfluorocarbons similarly reduce the need for allogenei

164 ets are injected into a low refractive index perfluorocarbon so that they can be optically trapped.

165 itives in the aqueous phase and carboxylated perfluorocarbon surfactants in the oil phase.

166 The perfluorocarbons tetrafluoromethane (CF(4), PFC-14) and

167 sonosensitive agents, encapsulating a liquid perfluorocarbon that would instantaneously vaporize at b

168 the quantitative measurement of atmospheric perfluorocarbon trace species at the sub part per quadri

169 The perfluorocarbon-treated animals had a significantly lowe

170 Upon pulsed laser irradiation, liquid perfluorocarbon undergoes a liquid-to-gas phase transiti

171 After 2 to 9 days on ECLS, perfluorocarbon was administered into the trachea until

172 No leakage of perfluorocarbon was noted in the new silicone fiber gas

173 Perfluorocarbon was then instilled via the endotracheal

174 in which the airspace was filled with inert perfluorocarbon, was reduced more than 10-fold in AQP1 (

175 ometer using 25 ppm of NO, 50 ppm of NO, and perfluorocarbon were within +0.25%, -0.7%, and +0.4%, re

176 lently tethered, flexible molecular layer of perfluorocarbon, which holds a thin liquid film of medic